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Abstract
During development the human β-globin gene cluster undergoes two switching 
processes at the embryo-fetal and fetal-adult stages, respectively, involving changes 
in chromatin remodeling and in transcriptional regulatory networks. In particular, 
during the perinatal period, the switch from fetal-to-adult globin gene expression 
leads to fetal globin genes silencing and progressive decline of fetal hemoglobin 
(HbF). Impaired hemoglobin switching is associated with hereditary persistence 
of HbF (HPFH), a condition in which the fetal globin genes fail to be completely 
silenced in adult red blood cells. This condition, when co-inherited with hemoglo-
binopathies, has great therapeutic potential because elevated HbF levels can amelio-
rate β-thalassemia and sickle cell anemia. Therefore, there is a growing interest 
about the complex network of factors that regulate fetal globin genes expression. 
Here we discuss the activity of transcriptional repressors of fetal globin genes and 
their potential role as novel therapeutic targets in β-thalassemia.
Keywords: globin gene switching, HbF silencing, LCR, transcriptional repressors, 
genome editing
1. Introduction
The human β-globin locus consists of five functional genes, HBE, HBG2, HBG1, 
HBD, and HBB, positioned on chromosome 11 in the same order in which they are 
expressed during ontogenesis. This fascinating process that regulates changes in 
the globin gene expression, referred to as globin gene switching, is programmed in 
order to produce different hemoglobin molecules able to meet the changing oxygen 
demand of the developing organism [1]. According to this process, up to the eighth 
week of pregnancy, the embryonic globin gene (HBE) is predominantly expressed 
in the primitive erythroblasts, large nucleated erythroid cells originating in the yolk 
sac. Approximately between the sixth and eighth week of pregnancy, fetal liver 
assumes the hematopoietic role and produces small, enucleated erythroid cells. The 
transition of hematopoiesis from the yolk sac to the fetal liver coincides with the 
switch from the embryonic HBE gene to the fetal globin genes (HBG1 and HBG2). 
At the perinatal period, the bone marrow becomes the principal site of hematopoiesis 
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and generates mature red blood cells. In conjunction with the transition from liver to 
bone marrow hematopoiesis, the second globin gene switch occurs from the fetal-to-
adult globin genes (HBD and HBB) in which fetal hemoglobin (HbF) production 
gradually declines to be replaced by the adult type (HbA) [2].
In the last decades, large research efforts have been devoted to disclose the 
molecular mechanisms underlying this switching process, thus revealing how it 
is under the tight control of complex interactions involving dynamic changes 
in chromatin remodeling as well as in transcriptional regulatory networks. 
Nevertheless, it is rather common that residual amount of fetal globin genes contin-
ues to be expressed throughout adult life with the majority of adults having traces 
of HbF (approximately 1% of total hemoglobin). Impairment of this fetal-to-adult 
hemoglobin switching process, whose molecular basis has been associated with a 
heterogeneous group of inherited defects, leads to hereditary persistence of fetal 
hemoglobin (HPFH) in adult life. Based on clinical and genetic observations that 
HPFH has ameliorative effects in β-thalassemia and in sickle cell anemia (SCD), 
interest has been growing regarding the therapeutic potential of fetal globin gene 
reawakening for these disorders [3–5]. Therefore, much effort is currently under-
way in order to further clarify the molecular basis of hemoglobin switching and 
persistence of high HbF levels in adult life.
Fetal hemoglobin levels are regulated by complex mechanisms involving factors 
linked or not to the β-globin gene (HBB) locus. Several genetic determinants in cis 
to the HBB cluster, including large deletions in the HBB cluster or single nucleotide 
sequence variations in the regulatory regions of the fetal globin genes, are known 
to influence HbF levels [6, 7]. Also, HPFH quantitative trait loci (QTL) unlinked to 
the HBB cluster have been so far identified as being involved in the transcriptional 
control of fetal globin genes. In particular, in the last years, great attention has been 
focused on two genetic determinants, the HBS1L-MYB intergenic region located 
on chromosome 6q23 and the gene coding for the oncogenic transcriptional factor 
BCL11A on chromosome 2p16 that act as main QTLs in influencing HbF levels [8].
Below we discuss the contribution of some of the main cis- and trans-acting 
determinants so far identified in silencing fetal globin gene expression and the most 
recent therapeutic advances based on fetal globin gene reactivation in the treatment 
of hemoglobinopathies.
2.  Regulatory elements and transcriptional factors involved in fetal 
globin gene silencing
2.1  The role of the locus control region (LCR) in chromatin remodeling and 
globin gene switching
The locus control region (LCR), located upstream of the HBE gene, represents 
the major regulatory element in the β-globin gene locus. It plays a key role in the 
switching process by controlling the transcription state of the locus as well as 
the transcription activity of each gene, thus conferring tissue- and stage-specific 
expression of the globin genes [9, 10].
The LCR contains five DNAse I hypersensitive sites (HS 1–5), four of which 
(HS1–HS4) acting as erythroid cell-specific enhancers that are required for proper 
order of activation of the globin genes during ontogeny. However, differently from 
classical enhancer elements, LCR activity is both orientation- and distance-depen-
dent and prevents position effects, therefore also indicating an insulator function 
for this regulatory region [9]. The last hypersensitive site (HS5) has a different role, 
acting as a structural and insulator element. Indeed, in erythroid cells it is closely 
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positioned to another hypersensitive site located at the opposite end of the HBB 
locus (3′HS1) to form an active chromatin hub that allows highly efficient globin 
gene transcription [10, 11].
It is now generally accepted that globin gene switching can occur through not 
mutually exclusive mechanisms involving direct competition between stage-spe-
cific gene promoters for LCR enhancer elements, gene expression activation, and/
or silencing mechanisms promoted by specific activators and repressors as well as 
by epigenetic modifications. By chromatin conformation capture (3C) experiments, 
it has been shown that LCR exerts long-distance transcriptional enhancement 
through dynamic organization of the locus in stage-specific chromatin loops that 
allow the LCR enhancers to be positioned in close proximity of the genes that are 
to be activated [12]. This mechanism is also consistent with the evidence that the 
LCR can interact with only one promoter at a time. These interactions also strictly 
depend on the availability of specific trans-acting factors, non-DNA-binding fac-
tors linked to transcription factors and chromatin facilitators bound to regulatory 
regions of genes to be transcribed (Figure 1).
It has also been shown that epigenetic mechanisms at the HBB locus are involved 
in gene expression control. One of these mechanisms involves DNA and histone 
methylation processes that are generally associated with the repression state of 
globin genes in non-erythroid cells as well as with the erythroid stage-specific 
silencing of globin gene expression within the activated chromatin hub [13]. 
Recently, HS4 in LCR was found to regulate another important stage-specific 
epigenetic mechanism of gene expression control by contributing to drive the 
recruitment of different histone acetylation/deacetylation enzymatic activities 
at specific regulatory regions, with acetylation being a general hallmark of gene 
Figure 1. 
Different molecular mechanisms proposed for LCR long-distance transcriptional enhancement through 
dynamic organization of the locus in stage-specific chromatin loops that allows the LCR enhances to be 
positioned in close proximity of the genes that are to be activated [9–12]. (A) The looping model is based on 
the concept that LCR acts as a holocomplex to stimulate gene expression by looping through the chromatin to 
activate the transcription machinery of a single gene at any given time. In this model, individual globin gene 
promoters are thought to compete for LCR activity. (B) The linking model requires the presence of a continuous 
protein chain from the LCR to the gene to be transcribed involving sequential stage-specific binding of 
transcriptional factors as well as of chromatin modifiers to define the chromatin region to be transcribed. (C) 
The tracking model is based on the idea that a signal such as an enhancer-bound protein complex comprising 
RNA polymerase II or histone modifiers is able to scan the DNA until a promoter is encountered to activate 
gene expression, with inactive genes looped out. (D) In the facilitated-tracking model, concepts of both the 
looping and tracking models are incorporated. In this model, enhancer-bound complexes track along DNA and, 
when the promoter of a to-be-transcribed gene is encountered, a stable DNA loop structure is formed.
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activation and, on the contrary, deacetylation being associated with gene repression 
mechanisms. More recently, it has also been found that histone acetylation, besides 
activating high-level gene transcription, also contributes to the formation of 
specific chromatin looping leading to an open chromatin configuration at the HBB 
locus. Furthermore, it has also been proved that loss of histone acetylation increases 
methylation both in the LCR and in fetal globin genes, thus reinforcing the silenc-
ing mechanisms of these epigenetic modifications [11].
Chromatin looping, transcriptional protein complexes, and epigenetic modifica-
tions require a large array of protein factors whose list grows continuously, thus 
providing deeper insights into these mechanisms. The role of some of the most 
relevant of them will be herein discussed.
2.2 Cold-shock domain protein A (CSDA)
Cold-shock domain (CSD) proteins have been reported to be largely involved in 
a variety of gene expression regulation processes such as transcriptional activation 
and repression or posttranscriptional mechanisms including mRNA packaging, 
transport, localization, and stability. In these proteins the CSD domain does not 
bind to unique DNA sequence motifs, but it is able to recognize intramolecular 
triplex H-DNA structures, commonly generated by CT-rich sequences. The cold-
shock domain protein A (CSDA), also known as DNA-binding protein A (dbpA), is 
a protein with a molecular weight of about 60 kDa [14]. The CSDA gene is located 
at position 12p13.1 and comprises 10 exons spanning a 24-kb genomic region. CSDA 
consists of three structural domains: an alanine/proline (AP)-rich N-terminal 
domain followed by a central cold-shock domain (CSD) and a C-terminal domain, 
containing four alternating clusters of basic and acid amino acids. The DNA-
binding domain is encoded by exons 1–5. Within this region, the cold-shock 
domain, comprising about 70 amino acid residues, is encoded by exons 2–5 [14]. 
A RNP1 motif [GA] – [FY] – [GA] – [FY] – [IVA], conserved in this protein fam-
ily [15], is present in the 3′ end of exon 2. The exon 6, encoding 69 amino acids, 
is alternatively spliced. The C-terminus (exons 6–9) C-terminal domain mediates 
protein-protein interactions [16]. Alternative splicing of exon 6 results in two main 
isoforms, namely, CSDA isoform a and isoform b, respectively, showing differ-
ent C-terminal domains and thus potentially able to take part to specific protein 
complexes [14, 16].
Figure 2. 
Binding of the transcriptional repressor CSDA to the −200 promoter region of HBG2 in adult erythropoiesis is 
impaired by HPFH mutations [18–22].
5Transcriptional Repressors of Fetal Globin Genes as Novel Therapeutic Targets in Beta…
DOI: http://dx.doi.org/10.5772/intechopen.90762
CSDA acts as a repressor of many cellular genes including the human granulocyte-
macrophage colony-stimulating factor (GM-CSF), an important hematopoietic 
growth factor [17]. More recently, it has been demonstrated that CSDA acts as a repres-
sor of fetal globin gene expression by binding a region −200 bp upstream of the HBG2 
gene [18] (Figure 2). This region consists of alternating homopurine and homopyrim-
idine tracts generating an H-DNA structure [19]. Mutations (HBG2 -200 C → G, −202 
C → T, −196 C → T e − 195 G → A) that destabilize the intramolecular triplex struc-
ture have been found associated with HPFH [20]. Previous studies had suggested that 
disruption of the intramolecular triplex could abolish CSDA binding sites conditions 
in this HBG2 promoter region [19, 21, 22], thus leading to persistent expression of fetal 
hemoglobin in adult life [19]. Based on RNA interference (RNAi) and overexpression 
studies in human erythroleukemia K562 cells and in primary erythroid cells, CSDA 
was demonstrated to directly play a repression role in HBG expression [18]. In fact, 
down- and up-modulation of CSDA levels consistently corresponded to variations of 
HBG expression levels: CSDA knockdown induced by RNAi resulted in significantly 
increased expression of HBG genes, whereas its overexpression was associated with 
reduced HBG mRNA levels. Also, chromatin immunoprecipitation (ChiP) analysis 
in K562 cells showed that CSDA interacts with this promoter region, thus confirming 
that CSDA modulates HBG expression at the transcriptional level [18]. Subsequently, 
it has been proposed that NF-kB and histone deacethylase 2 (HDAC2) interact with 
CSDA to form a multiprotein complex which take part to the regulation of HBG2 
expression by modulating local chromatin conformation [23], thus highlighting the 
relevance of the role played by CSDA in fetal globin gene expression and shedding 
novel light on the molecular mechanisms involved in globin gene switching (Figure 3).
2.3 B-cell lymphoma/leukemia 11A (BCL11A)
The B-cell lymphoma/leukemia 11A (BCL11A) is a multiple zinc-finger transcrip-
tion factor encoded on chromosome 2p15, previously reported as being implicated 
in B-lymphocyte production and neurodevelopment [28]. More recently, genome-
wide association studies (GWAS) identified single nucleotide polymorphisms 
(SNPs) in intron 2 of the BCL11A gene as strictly associated with HPFH conditions, 
thus revealing a hitherto unexplored but crucial role of BCL11A in HbF silencing 
[29]. Indeed, as was later demonstrated, such SNPs are able to disrupt erythroid-spe-
cific enhancer elements required for high-efficient expression of the BCL11A gene 
[30]. Similarly to CSDA, BCL11A knockdown experiments performed in K562 cells 
and in human erythroblasts led to increased expression of fetal globin genes, thus 
providing further evidence that this factor acts as a repressor of HbF expression.
In the last years, many efforts have been aimed at clarifying the repression 
mechanism exerted by BCL11A at the HBB locus. At this regard, an important 
contribution has been provided by the identification of the multiprotein complex 
Figure 3. 
Transcriptional repressor mechanisms of fetal globin genes in adult erythropoiesis involving BCL11A and 
CSDA multiprotein complexes [23–27].
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interacting with BCL11A that includes GATA-1, FOG-1, RUNX1, KLF1, and SOX6 
[24, 31, 32]. In addition, further insights have been provided regarding the BCL11A 
repression mechanisms by demonstrating how these protein complexes drive the 
recruitment of a variety of epigenetic factors such as the nucleosome remodel-
ing and deacetylase (NuRD) repressor complex, histone deacetylase (HDAC1 
and HDAC2), lysine-specific demethylase (LSD1), and DNA methyl-transferase 
(DNMT1) [25–27] (Figure 3). ChiP analysis also revealed binding sites for BCL11A 
at regulatory elements within the LCR, as well as at the promoter regions of both 
embryonic and fetal globin genes and in an intergenic region between the fetal and 
adult genes, thus indicating that these protein complexes are directly involved in 
fetal globin gene silencing as well as in long-range interactions that contribute to 
reshape chromatin loop domains in order to spatially separate the fetal and adult 
globin genes from the transcriptional machinery and, in the meantime, to promote 
long-range LCR interactions with the adult globin genes [33–35].
2.4 Krüppel-like factor 1 (KLF1)
The transcription factor KLF1 (Krüppel-like factor 1), formerly known as 
erythroid Krüppel-like factor (EKLF) for its restricted expression in erythroid cells 
and its similarity to the protein encoded by the Drosophila segmentation Krüppel 
gene), plays a multifunctional role in the regulation of a variety of cellular events 
leading to erythroid differentiation, including erythroid lineage commitment, 
heme synthesis, and globin gene switching [36–39].
The KLF1 gene (~3kb) is located on chromosome region 19p13.2 and consists 
of three exons encoding a 362 amino acid protein with an N-terminal region rich 
in proline residues and containing two short transactivation domains (TAD1 
and TAD2) and a C-terminus with three highly conserved Cys2/His2 zinc-
finger domains (ZF1, ZF2, and ZF3) that interact with the DNA sequence motif 
5′CCMCRCCCN3′ located in CACCC boxes and GC-rich elements in the regulatory 
regions of its target genes [38].
In the HBB cluster, KLF1 exerts a dual role in fetal-to-adult globin gene switch-
ing by different mechanisms. On one hand, as also evidenced by studies on (+/−) 
KLF1 transgenic mice [12], KLF1 contributes to directly activate the HBB gene in 
adult life by inducing the formation of chromatin loops that relieve the HBB gene 
from competition with the HBG genes and favor interactions of the HS2 and HS3 
sites in the LCR with the HBB promoter region [40]. On the other hand, KLF1 
indirectly contributes to silencing fetal globin gene expression through the activa-
tion of BCL11A, a repressor of HBG globin genes transcription, as described above. 
To date, more than 65 loss-of-function mutations have been reported for the KLF1 
gene, most of which are missense mutations found largely within the three zinc-
finger domains [41]. Mutations in the KLF1 gene have been reported to interfere 
with its functions in the erythropoiesis process, thus leading to a wide range of 
hematological phenotypes, including high borderline HbA2 levels, mild microcyto-
sis, and/or hypochromia but also, importantly, with persistence of fetal hemoglobin 
expression in adult life. It is thus not surprising that, although identification of 
carriers of KLF1 mutations may be quite challenging because their phenotypic 
traits do not present relevant clinical implications, the majority of KLF1 muta-
tions have been detected in populations at risk for hemoglobinopathies according 
to the evidence that defective KLF1 activity can lead to impaired HbF silencing 
with ameliorating effects in SCD and in β-thalassemia. Therefore, KLF1 mutations 
have been considered as a natural model of impaired hemoglobin switching, and, 
accordingly, KLF1 has been proposed as a new potential therapeutic target in these 
diseases [39, 42].
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2.5 Myb
Myb is a DNA-binding transcriptional regulator of approximately 75 kDa that 
plays a crucial role in hematopoiesis and erythropoiesis. The MYB gene is located 
on chromosome 6q23 and codifies for a protein with three functional domains: a 
highly conserved DNA-binding domain (DBD) near its N-terminus that recognizes 
and binds the consensus sequence PyAACG/TG, a central transactivation domain 
(TAD), and a C-terminal negative regulatory domain (NRD) containing a leucine 
zipper motif important for homodimeration and for protein interactions [43].
A large variety of proteins have been identified so far as Myb interactors: DNA-
binding transcription factors that directly bind Myb, transcriptional coactivators 
that mediate interactions with the transcriptional machinery, and protein factors 
that are able to modify Myb activity. Each of these of protein factors can act either 
as activator or repressor of Myb function, depending both on cell type and protein 
microenvironment [43].
In the last decade, a GWAS approach led to the identification of a set of single 
nucleotide polymorphisms at the HBS1L-MYB intergenic region, subsequently iden-
tified as HMIP-2, displaying a strong association with persistence of fetal hemoglo-
bin in adult life [44–46]. By demonstrating that these SNPs disrupt binding sites at 
key erythroid enhancers and cause reduced Myb expression levels, it was possible 
to provide an explanation for the association of the HMIP-2 region with HbF levels 
and, in the meantime, to identify Myb as a negative regulator of fetal globin genes.
Notably, further evidence of the repressive role of Myb on fetal globin gene 
expression has also been provided by clinical observations of higher HbF levels in 
patients with trisomy 13. It has been demonstrated that in this condition, the high 
HbF levels are related to the dysregulation of two microRNAs, miR-15a and miR-
16-1, both localized on chromosome 13q14, which mediate Myb downregulation 
through the binding to its 3′-UTR region [47].
Nevertheless, in spite of all these evidences, the mechanism of repression of 
fetal globin genes exerted by Myb is not fully understood. It has been proposed that 
Myb could regulate HbF expression by two not mutually exclusive mechanisms: by 
activating the expression levels of fetal globin gene repressors as BCL11A and KLF1 
or by controlling the kinetics of erythroid differentiation. In fact, low Myb levels 
have been found associated with reduced levels of these HBG repressors and also 
with accelerated erythroid differentiation leading to the release of early erythroid 
progenitor cells that are still synthesizing predominantly HbF [48]. Furthermore, 
it has also been found that Myb and BCL11A cooperate with DNMT1 to achieve 
developmental repression of embryonic and fetal globin genes in adult erythro-
poiesis [25], thus supporting the evidence that the network of factors involved in 
fetal globin gene silencing converges on common mechanisms and cooperates at 
different levels to sustain globin gene switching and to reinforce the process of HbF 
repression.
3. Novel therapeutic approaches for β-thalassemia
Currently, clinical management of β-thalassemia and SCD patients is largely 
dependent on regular blood transfusions associated with chelating agents for the 
treatment of systemic iron overload. Indeed, except for allogeneic transplantation 
strategies, whose favorable outcome is anyway restricted to the availability of a 
well-matched donor, or for the more recent haploidentical transplantation option 
that however carries substantial risks, no other curative option is currently avail-
able for hemoglobinopathies. Therefore, due to the relevant global health burden 
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of these diseases, there is still a great need for effective and definitive large-scale 
treatments.
In the last decades, given the ameliorative effects of elevated HbF levels that 
can lead to decreased hemoglobin polymerization in SCD as well as to reduced 
α-chain imbalance in β-thalassemia, a great deal of effort has been devoted to the 
development of new therapies aimed at reactivating fetal globin gene expression. 
Therefore, according to the evidences that hypo-methylated DNA and hyper-acety-
lated histones are well-known epigenetic marks of transcriptionally active regions, 
inhibitors of DNA methyltransferase (DNMT) and histone deacetylase (HDAC) 
have been developed as novel pharmacologic approaches to support transfusion 
therapy. Among the first drugs to be identified, 5-azacytidine and decitabine were 
found to induce increased HbF levels through DNA hypo-methylation process. 
Subsequently, the use of hydroxyurea (HU) was also investigated as a promising 
HbF inducer agent in adults with severe SCD. Although the mechanism through 
which HU induces HbF reactivation is still not completely understood, HU treat-
ment was found to increase HbF levels and reduce HbS polymerization, thus 
improving clinical symptoms and quality of life of these patients. Another epigen-
etic approach was also exploited through the use of HDAC inhibitors, including 
butyrate and its derivatives that have been demonstrated to stimulate HbF produc-
tion in β-thalassemia patients [49].
More recently, many hopes were directed toward the development of gene 
therapy procedures designed to introduce a normal copy of the β-globin gene by viral 
vectors that offer the advantages of long-term benefits and, even more importantly, 
being based on autologous transplant, do not require a matched donor. However, in 
spite of great expectations for a rapid development of this approach, for many years 
it proved a difficult goal, and only recently it has been successfully introduced in clin-
ical practice. Notably, during the last years, additional promising therapeutic options 
have been provided by progress in gene-editing technologies, including the clustered, 
regularly interspaced, short palindromic repeat (CRISPR)-CRISPR-associated 9 
(Cas9) (CRISPR-Cas9) tool, designed to introduce highly specific genome modifica-
tions for either gene disruption or correction [48, 50, 51]. At the same time, progress 
in understanding the molecular mechanisms underlying fetal globin gene silencing 
has contributed to identify several potential molecular targets, thus paving the way 
to novel therapeutic approaches for hemoglobinopathies that, besides correcting the 
defective β-globin gene, are now aimed at editing genomic segments that regulate 
fetal hemoglobin synthesis in hematopoietic stem cells (HSCs).
Interestingly, some of the most promising editing strategies for hemoglobin-
opathies that are being pursued include the reactivation of fetal globin genes that 
could be achieved either by silencing fetal globin gene repressors or, alternatively, 
by introducing known HPFH mutations in the HBB cluster. Since the beginning, 
targeting Myb or KLF1 appeared to be rather problematic given the pleiotropic roles 
played by these two factors in hematopoiesis and in erythropoiesis, respectively, 
whereas BCL11A emerged as one of the most appropriate candidate to be silenced, 
given its well-recognized role in HbF repression [48, 50, 51]. However, ubiquitous 
BCL11A knockdown rapidly turned out to be an unsuccessful strategy, given its role 
in other biological pathways including neuronal and B-lymphocyte development 
[28]. Consequently, alternative strategies are being underway focused on reducing 
its expression selectively in erythroid cells that could be achieved by disruption of 
its intronic erythroid-specific enhancer without affecting non-erythroid cells [51]. 
A similar approach could also be used to tune down Myb expression levels by edit-
ing SNPs at the HBS1L-MYB intergenic region that are known to disrupt the struc-
ture and the functionality of erythroid-specific enhancers causing reduced Myb 
expression levels. Anyway, other repressors such as CSDA or erythroid-specific 
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cofactors could represent potential suitable candidates to be considered for novel 
genome-editing strategies. Furthermore, genome-editing procedures leading to 
the introduction of KLF1 mutations that emerged as a natural model of impaired 
hemoglobin switching or HPFH mutations in the regulatory regions of fetal globin 
genes have been proposed either as alternative or supportive therapeutic strategies 
to induce clinically significant increases in HbF levels [48, 50, 51].
4. Conclusions
The research in this field should be immediately focused on the development of 
safe, effective drug therapies that can be accomplished through fetal globin gene 
induction and at the same time on the prospect of cures through bone marrow 
transplantation using the promise of genome-editing strategies that will bring 
a vastly improved quality and quantity of life to patients who suffer from these 
devastating disorders.
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